The May acqusition will have around a 6 month contribution to the revised guidance , ie. $186K EBITDA and the contribution of the $1,044,000 EBITDA from the 2 centres just purchased in CY 18 will be neglible as they don't settle till later in the year. So only around $15oK NPAT is baked into the guidance with $620K NPAT to come in CY19
Director buying, page-14
Add MFD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.24M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40000 | 50.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.0¢ | 2619 | 1 |
View Market Depth
| Last trade - 16.17pm 29/11/2024 (20 minute delay) ? |
| MFD (ASX) Chart |
Day chart unavailable
